公司简介
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for...
关联新闻
- Incyte says EU approves oral treatment for chronic skin disease
Incyte said on Monday the European Commission had approved its once-daily oral therapy for a type of chronic skin disease.
- Incyte Sales Growth Drives Share Price Gains
Biopharmaceutical company Incyte Corporation (INCY) gets Big Money support to gain 23% so far in 2026.